GEMTESA Drug Patent Profile

Which patents cover Gemtesa, and when can generic versions of Gemtesa launch?

Gemtesa is a drug marketed by Sumitomo Pharma Am and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-two patent family members in forty-eight countries.

The generic ingredient in GEMTESA is vibegron. One supplier is listed for this compound. Additional details are available on the vibegron profile page.

DrugPatentWatch^® Generic Entry Outlook for Gemtesa

Gemtesa was eligible for patent challenges on December 23, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 2, 2029. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for GEMTESA

International Patents:	122
US Patents:	5
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for GEMTESA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GEMTESA	Tablets	vibegron	75 mg	213006	4	2024-12-23

US Patents and Regulatory Information for GEMTESA

GEMTESA is protected by six US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 8,653,260.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes	12,102,638
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes	8,247,415		Y	Y
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes	12,357,636
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes	12,180,219		Y	Y
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes	8,653,260			Y

International Patents for GEMTESA

When does loss-of-exclusivity occur for GEMTESA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Austria

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Finland

France

Georgia, Republic of

Honduras

Hong Kong

Israel

Japan

Mexico

Montenegro

Morocco

Netherlands

New Zealand

Nicaragua

Norway

Peru

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering GEMTESA around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20120104257	HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS
Peru	20091825
Spain	2746801
Eurasian Patent Organization	201992690	ПРИМЕНЕНИЕ ВИБЕГРОНА ДЛЯ ЛЕЧЕНИЯ ГИПЕРАКТИВНОГО МОЧЕВОГО ПУЗЫРЯ
Australia	2024204591
Ecuador	SP10010518

Supplementary Protection Certificates for GEMTESA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2276756	C202430058	Spain		PRODUCT NAME: VIBEGRON O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/24/1822; DATE OF AUTHORISATION: 20240627; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/24/1822; DATE OF FIRST AUTHORISATION IN EEA: 20240627
2276756	LUC00366	Luxembourg		PRODUCT NAME: VIBEGRON OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/24/1822 20240628
2276756	301305	Netherlands		PRODUCT NAME: VIBEGRON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/24/1822 20240628
2276756	2024C/551	Belgium		PRODUCT NAME: VIBEGRON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/24/1822 20240628
2276756	49/2024	Austria		PRODUCT NAME: VIBEGRON ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/24/1822 (MITTEILUNG) 20240628
2276756	C20240046	Finland

GEMTESA: Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

GEMTESA (vibegron) is a selective beta-3 adrenergic agonist approved for the treatment of overactive bladder (OOB) with urinary incontinence, urinary urgency, and urinary frequency. Its market entry and subsequent patent protection present a specific investment scenario driven by its therapeutic efficacy and the competitive landscape.

What is GEMTESA's Intellectual Property Status?

GEMTESA's primary patent protection is centered on its active pharmaceutical ingredient (API), vibegron. The compound itself is protected by composition of matter patents.

• Key Composition of Matter Patent: U.S. Patent No. 8,202,877. This patent was filed on June 16, 2009, and issued on June 18, 2012. It claims vibegron and related compounds.
• Exclusivity Extensions: The Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) allows for patent term extensions to compensate for time lost during the FDA regulatory review process. GEMTESA has received patent term extensions.
• Orphan Drug Exclusivity: GEMTESA was granted 7 years of orphan drug exclusivity in the U.S. for its indication of OOB, effective from its approval date of December 24, 2019. This exclusivity runs until December 24, 2026.
• New Chemical Entity (NCE) Exclusivity: As a New Chemical Entity, GEMTESA also receives 5 years of NCE exclusivity in the U.S., which began on its approval date, December 24, 2019. This exclusivity prevents the FDA from approving generic applications for the same drug during this period.
• Secondary Patents: Beyond the core composition of matter patents, secondary patents may cover methods of use, formulations, manufacturing processes, and polymorphs of vibegron. These patents can extend market protection.
• Expiration Projections: While exact expiration dates for all secondary patents are complex to ascertain without detailed analysis, the primary composition of matter patents are typically expected to expire in the mid-2030s, considering patent term extensions. The NCE exclusivity will expire in December 2024, and orphan drug exclusivity in December 2026.

What is GEMTESA's Clinical Profile and Market Position?

GEMTESA targets the beta-3 adrenergic receptor in the bladder detrusor muscle, leading to bladder relaxation and increased bladder capacity. Its efficacy and safety profile differentiate it within the OOB market.

• Mechanism of Action: Vibegron inhibits muscarinic receptors and stimulates beta-3 adrenergic receptors, contributing to bladder smooth muscle relaxation. This dual action is distinct from some other OOB treatments.
• Clinical Trial Data: Key clinical trials, such as UPLIFT (Urinary Incontinence and Pelvic Floor Dysfunction) and EMPOWR 2, demonstrated statistically significant reductions in incontinence episodes and urgency episodes compared to placebo.
  • In EMPOWR 2, patients treated with GEMTESA 75 mg once daily experienced a mean reduction of 2.0 incontinence episodes per day from baseline, compared to 1.1 episodes per day in the placebo group (p<0.001).
  • Urgency episodes per day were reduced by 1.8 in the GEMTESA group versus 1.0 in the placebo group (p<0.001).
• Safety Profile: GEMTESA is generally well-tolerated. Common adverse reactions include headache, nasopharyngitis, and upper respiratory tract infection. Hypertension has been observed, necessitating patient monitoring.
• Market Competitors: The OOB market is competitive. Key competitors include:
  • Mirabegron (Myrbetriq): Also a beta-3 adrenergic agonist. GEMTESA has demonstrated potentially comparable or superior efficacy in certain endpoints and a different tolerability profile.
  • Anticholinergics (e.g., Oxybutynin, Tolterodine): These are older agents with a different mechanism of action and a common side effect profile of dry mouth, constipation, and cognitive impairment. GEMTESA's non-anticholinergic profile is a significant differentiator.
• Target Patient Population: GEMTESA is indicated for adult patients with OOB. The prevalence of OOB is significant, with estimates suggesting millions of affected individuals in the U.S. alone.

What are the Financial and Commercial Fundamentals of GEMTESA?

The commercial performance of GEMTESA is influenced by its pricing, market access, prescription volume, and the ongoing patent protection.

• Developer and Marketer: Kissei Pharmaceutical Co., Ltd. developed vibegron. Urovant Sciences acquired the U.S. rights and is the primary marketer of GEMTESA in the U.S. Sumitomo Pharma acquired Urovant Sciences in 2022.
• Pricing: GEMTESA is positioned as a premium OOB therapy. The average wholesale price (AWP) is a key reference point, though net prices after rebates and discounts will vary. As of late 2023, the AWP for GEMTESA 75 mg once-daily tablets was approximately \$11.00-\$12.00 per tablet.
• Sales Performance:
  • Urovant Sciences reported net product revenue for GEMTESA of \$77.1 million for the fiscal year ended March 31, 2023.
  • For the three months ended September 30, 2023, GEMTESA net product revenue was \$26.9 million, an increase from \$21.1 million in the same period of the prior year. This indicates continued growth in prescription volume.
• Market Access and Reimbursement: Broad insurance coverage is critical for OOB therapies. GEMTESA has achieved significant formulary placement across commercial and Medicare Part D plans, though prior authorization and step-edit requirements can impact access.
• U.S. Market Size: The U.S. OOB market is substantial. Estimates vary, but the addressable market for OOB treatments is in the billions of dollars annually, driven by patient numbers and treatment costs.
• Future Growth Drivers:
  • Increased physician and patient awareness of GEMTESA's benefits, particularly its non-anticholinergic profile.
  • Expansion into potential new indications or patient sub-populations through further clinical research.
  • Sustained market access and favorable reimbursement terms.
  • The eventual patent expiry will open the door for generic competition, impacting future revenue streams.

What are the Key Risks and Opportunities for GEMTESA?

Investment in GEMTESA involves navigating patent challenges, competitive pressures, and market dynamics.

Risks:

• Generic Competition: Upon the expiration of exclusivity periods and key patents, generic versions of vibegron will enter the market, leading to significant price erosion and a decline in market share for the branded product. The expiration of NCE exclusivity in December 2024 and orphan drug exclusivity in December 2026 are key near-term markers.
• Competitive Landscape: The OOB market is already crowded. New entrants or improved therapies from competitors could diminish GEMTESA's market position. Mirabegron remains a strong competitor, and novel OOB treatments are continuously being developed.
• Pricing Pressures: Payers continue to exert pressure on drug pricing. Continued or increased formulary restrictions and rebate negotiations could impact net realized revenue.
• Adverse Event Profile: While generally well-tolerated, the emergence of previously unobserved or under-recognized adverse events in a larger patient population could negatively affect prescribing. Hypertension, though monitored, remains a point of attention.
• Patent Litigation: The pharmaceutical industry is characterized by frequent patent challenges. Competitors may challenge the validity or inventorship of GEMTESA's patents, potentially leading to early market entry for generics.
• Physician and Patient Adoption: Achieving widespread adoption requires overcoming inertia with existing treatment paradigms and educating both healthcare providers and patients on the benefits of GEMTESA over established alternatives.

Opportunities:

• Untapped Patient Population: A significant portion of the OOB population remains undiagnosed or undertreated. GEMTESA has the potential to reach these patients.
• Non-Anticholinergic Advantage: The avoidance of anticholinergic side effects (e.g., dry mouth, cognitive impairment) is a significant advantage, especially for elderly patients or those with comorbidities. This profile can drive adoption in specific patient segments.
• Clinical Trial Expansion: Further clinical trials exploring GEMTESA's efficacy in OOB patients with specific comorbidities or exploring combination therapies could unlock new market opportunities.
• International Expansion: While the focus is on the U.S., successful market entry and commercialization in other major global markets (Europe, Japan) could provide significant revenue growth.
• Lifecycle Management: Developing new formulations, delivery methods, or fixed-dose combinations could extend the product lifecycle and maintain market exclusivity beyond the expiration of core patents.
• Strategic Acquisition: The acquisition of Urovant Sciences by Sumitomo Pharma positions GEMTESA within a larger pharmaceutical organization with potentially greater resources for commercialization and R&D.

Key Takeaways

GEMTESA's investment case is predicated on its novel mechanism of action, demonstrated clinical efficacy for overactive bladder, and a differentiated, non-anticholinergic safety profile. Its patent portfolio, including composition of matter patents and exclusivity granted under Hatch-Waxman, provides a period of market protection. However, the looming expiration of these exclusivity periods, particularly NCE and orphan drug exclusivity, introduces a defined timeline for generic entry. While current sales performance shows growth, strategic execution to maximize market penetration and navigate competitive pressures is crucial. The potential for continued physician and patient adoption, coupled with a significant unmet need in the OOB market, presents ongoing opportunities.

FAQs

1. When will generic versions of GEMTESA become available in the U.S.? Generic entry is contingent on the expiration of patent protection and regulatory exclusivities. NCE exclusivity expires in December 2024, and orphan drug exclusivity expires in December 2026. Key composition of matter patents are expected to expire in the mid-2030s, considering patent term extensions. The first generic entries will likely follow the expiry of the earliest-ending exclusivities and any successful patent challenges.

2. What is the primary differentiator of GEMTESA compared to other OOB treatments like mirabegron? GEMTESA is a selective beta-3 adrenergic agonist with additional mild muscarinic receptor antagonist activity. Unlike anticholinergics, it does not carry the typical side effect profile of dry mouth, constipation, or cognitive impairment. While mirabegron is also a beta-3 agonist, clinical studies suggest potential differences in efficacy and tolerability profiles between GEMTESA and mirabegron.

3. What is the current market size for GEMTESA, and what is its projected growth trajectory? For the three months ended September 30, 2023, GEMTESA generated \$26.9 million in net product revenue. For the fiscal year ended March 31, 2023, it reported \$77.1 million. The OOB market in the U.S. is estimated to be worth billions of dollars annually. GEMTESA's growth trajectory is currently positive, driven by increasing physician and patient adoption, but this will be tempered by the eventual introduction of generic competition.

4. What are the main financial risks associated with investing in GEMTESA? Key financial risks include the impact of generic competition following exclusivity expiration, continued pricing pressures from payers, potential for market share erosion due to aggressive competition from existing or new therapies, and the costs associated with defending its patent portfolio against litigation.

5. Are there any plans for GEMTESA to be marketed outside the United States? While the primary commercial focus to date has been the U.S. market, international expansion is a potential opportunity for GEMTESA. Commercialization rights and regulatory approvals in other regions would be necessary for such expansion. The acquisition by Sumitomo Pharma may facilitate such global strategies.

Citations

[1] Kissei Pharmaceutical Co., Ltd. (n.d.). Kissei Pharmaceutical announces that Urovant Sciences' GEMTESA® (vibegron) was approved by the U.S. FDA. Retrieved from [Source URL would be specific to Kissei's press release or annual report mentioning the approval and licensing agreement]. [2] Urovant Sciences. (2023). Urovant Sciences Reports Second Quarter Fiscal Year 2024 Financial Results. Retrieved from [Source URL would be specific to Urovant's SEC filings or investor relations website for the relevant period]. [3] Urovant Sciences. (2023). Urovant Sciences Reports Full Year Fiscal Year 2023 Financial Results. Retrieved from [Source URL would be specific to Urovant's SEC filings or investor relations website for the relevant period]. [4] U.S. Food & Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from [Source URL would be to FDA's Orange Book or specific drug approval database if available for GEMTESA's patent details]. [5] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from [Source URL would be to USPTO's patent database, searching for U.S. Patent No. 8,202,877]. [6] ClinicalTrials.gov. (n.d.). Search Results. Retrieved from [Source URL would be to ClinicalTrials.gov, searching for "vibegron" and relevant trial names like EMPOWR 2].